Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET-HF: Tofogliflozin mechanistic study in HFrEF with type 2 diabetes
jRCTs041210022Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tofogliflozin in type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF), sponsored by Kowa Company, Ltd. Primary endpoint: Change in late H/M ratio on I-123 MIBG scintigraphy. Started May 2021; status: completed.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCTs041210022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210022.